Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18683363 | 0.83 | EEF2K (0.46) | EEF2KMEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL27684813 | 0.80 | CTSA (0.37) | MEN1KMT2AGABBR2GABBR1CTSA | |
| SCHEMBL7423595 | 0.79 | GABBR2 (0.61) | MEN1KMT2AGABBR2GABBR1FNTA | |
| SCHEMBL5685248 | 0.78 | EEF2K (0.50) | EEF2KMEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL31520095 | 0.78 | CNR2 (0.43) | EEF2KMEN1KMT2ACNR2CES2 | |
| SCHEMBL29090661 | 0.76 | LMNA (0.39) | EEF2KMEN1KMT2AGAAFNTA | |
| SCHEMBL31378978 | 0.75 | CES2 (0.44) | MEN1KMT2ACNR2CES2CES1 | |
| SCHEMBL8770868 | 0.75 | CES2 (0.49) | EEF2KMEN1KMT2ACNR2CES2 | |
| SCHEMBL27509080 | 0.75 | FFAR1 (0.44) | MEN1KMT2AGABBR2GABBR1FNTA | |
| SCHEMBL10078181 | 0.74 | GABBR2 (0.50) | MEN1KMT2AGABBR2GABBR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| CN-101479241-A | Pyrrole derivatives and their methods of use | ABBOTT LAB (US) | 2009-07-08 | — | — | CN | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | PYGL, GYS2, G6PC1 | EEF2K 2110/4885MEN1 3728/4885KMT2A 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.